ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

ORYZF, a clinical-stage biopharmaceutical company focused on epigenetics, secured a U.S. patent grant for vafidemstat in treating non-aggressive symptoms of borderline personality disorder (BPD). Patent No. 12,673,044 extends through March 2043, incorporating 1,095 days of patent term adjustment, providing extended exclusivity for the therapeutic candidate in a historically underserved psychiatric indication.

The patent covers methods using LSD1 inhibitors—the company's core mechanism—for BPD symptomatology. Concurrent progress in the Canadian patent application strengthens international intellectual property positioning. This development reduces regulatory uncertainty for vafidemstat's clinical pathway and creates a meaningful moat around the asset, particularly important given the substantial unmet need in BPD treatment and limited FDA-approved options.

For a clinical-stage biotech, patent grants substantially de-risk the commercial timeline and provide investor confidence in asset longevity. The 17-year runway offers ample time for Phase trials, potential approval, and market exclusivity—critical for capital efficiency in psychiatric drug development, which typically requires lengthy clinical validation and post-approval monitoring.

Sector implication: Positive signals for psychiatric and rare neurological disorders attract investor interest in specialty pharma. However, ORYZF remains pre-revenue and highly speculative; the stock is thinly traded OTC. Market correlation remains low due to company-specific risk dominating macro factors. Incremental de-risking favors patient holders but does not alter fundamental biotech valuation dynamics or broad sector trends.